Black Diamond Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Black Diamond Therapeutics

09/05/2023 14:20

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a
quarterly
adjusted loss of 57 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 61 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 57 cents​.
    * The mean earnings estimate of analysts had fallen by
about 8.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Black Diamond Therapeutics Inc shares had risen by 1.6%
this
quarter and gained 6.7% so far this year.
    * The company reported a quarterly loss of $20.88 million.
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $4.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 01:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.61          -0.57          Beat
 Dec. 31 2022      -0.63          -0.59          Beat
 Sep. 30 2022      -0.64          -0.60          Beat
 Jun. 30 2022      -0.68          -0.63          Beat